Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions.

• Oct 14, 2019
  Come meet us at ACoP in Orlando next week. Drop by our booth to discuss model informed drug development with our experts and leaders. There are still opportunities for free speed consulting, should you want input to your strategic or hands-on work. Read more about this offer or sign up here.

• Sep 26, 2019
  This year, during the ACOP Meeting in Orlando, Pharmetheus will offer professional pharmacometric consulting sessions (~30 min), free of charge. Talk to us about Pharmacometrics, PBPK, Regulatory strategy, MIDD strategy, and much more! These sessions are open to everyone and independent of any current or future plans to use our services. Read more about this offer or sign up here. See you at ACOP, The Pharmetheus Team

• Sep 23, 2019
  Congratulations to our Advisor and Chairman of the Board, Prof. Mats Karlsson, who has been awarded the BCPT Nordic Prize 2019 for his deeds in the field of pharmacometrics, which has been of great importance for both science and education.

• Aug 27, 2019
  Pharmetheus continues to grow and we are very happy to announce the arrival of two new team members, Ari Brekkan, MIDD consultant, and Antonio Klaric, System administrator. Ari recently defended his PhD thesis at Uppsala University. His work focused on the application and use of pharmacometric models in the development of biological medicinal products. Antonio has experience in a variety of fields, such as managing virtual machines and providing system support to developers who used Python, PostgreSQL, PHP and MySQL. Very welcome to Pharmetheus!

• Jul 11, 2019
  

  A new talent joined our experienced team! We're excited to announce that Qing Xi, working more recently at the University of Otago, New Zealand, started at Pharmetheus.

• Jun 11, 2019
  Pharmetheus is at PAGE 2019 in Stockholm! We look forward to seeing you at booth no. 19-20.

• May 29, 2019
  A warm welcome to Robin Svensson, joining our MIDD consultants team! Robin recently graduated from Uppsala University with an important thesis work on how pharmacometrics can be used to improve decision-making for development and use of drugs against tuberculosis.

• May 22, 2019
  

  Pharmetheus is very happy to announce the addition of two new consultants to our growing team. Enrica Mezzalana joins us from Exprimo. Enrica has a PhD in Bioengineering and Bioinformatics and has been working for >5years as a pharmacometrician to support model informed drug development both in industry and in consultancy. She has experience in planning and conducting populationPK/PD analyses across different therapeutic areas as well as in building physiologically based models, applied primarily to DDI predictions. Tobias Kanacher also joins us from Exprimo. Tobias was formerly a consultant and Systems Pharmacology Expert at SGS Exprimo and Bayer. In that role he advised preclinical and clinical drug development teams how to apply PBPK modelling across different stages of clinical drug development. He contributed to the filing of new drug applications and has experience with regulatory interactions. Welcome to you both.

• Mar 8, 2019
  Pharmetheus possesses a blend of expertise to enhance model informed drug development (MIDD) at the trial, compound and/or organization level. We are able to offer a range of MIDD related services tailored to your needs, such as: Presentations focused on MIDD awareness Workshops focused on MIDD implementation Workshops focused on MIDD application within particular therapeutic areas Scientific advice at the analysis, trial and compound levels Delivery of a range of MIDD components in a “fit for purpose” manner   For more information please contact Marie Sandström and info@pharmetheus.com.

• Mar 8, 2019
  Pharmetheus is delighted to announce the appointment of Richard J Anziano as Chief Statistician. Rich was formerly Global Head of Statistics and Chief Statistician for Pfizer Inc. with responsibility for approximately 250 statisticians. In that role he led the quantitative assessment of late stage probabilities of technical and regulatory success through modeling and simulation for late-stage assets compared to industry/therapeutic area benchmarks. He was a long standing member of the cross PhRMA statistics group. He has over 25 years of drug development experience in Neuroscience, Pain, Cardiovascular, Infectious Disease, Rare Disease. He fostered a culture of collaboration and partnership across statisticians, clinical pharmacologists, and clinicians which enabled MIDD within Pfizer to effectively and efficiently support and inform development program strategies and decisions.